The prognostic value of single and repeated ≥10% FEV1 declines for chronic lung allograft dysfunction.

IF 6.4 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Heart and Lung Transplantation Pub Date : 2024-12-03 DOI:10.1016/j.healun.2024.11.031
Kimberly Lu, Miranda C Bradford, Xuanshuang Wang, Ted Liu, Chelsea Schmitz, Erika D Lease, Siddhartha Kapnadak, Ramsey Hachem, Kathleen J Ramos, Eric D Morrell
{"title":"The prognostic value of single and repeated ≥10% FEV<sub>1</sub> declines for chronic lung allograft dysfunction.","authors":"Kimberly Lu, Miranda C Bradford, Xuanshuang Wang, Ted Liu, Chelsea Schmitz, Erika D Lease, Siddhartha Kapnadak, Ramsey Hachem, Kathleen J Ramos, Eric D Morrell","doi":"10.1016/j.healun.2024.11.031","DOIUrl":null,"url":null,"abstract":"<p><p>There is a paucity of data reporting the positive and negative predictive values (PPV, NPV) of acute declines in lung function on chronic lung allograft dysfunction (CLAD). We sought to define the predictive ability of single or repeated forced expiratory volume in the first second (FEV<sub>1</sub>) declines for at least 3 weeks on the development of CLAD or death by 1-year. We analyzed 340 subjects with at least 3 years of follow-up data from two lung transplant centers. A single ≥10% FEV<sub>1</sub> decline had a PPV of 35% and NPV of 63%, and a repeated ≥10% FEV<sub>1</sub> decline for at least 3 weeks had a PPV of 44% and NPV of 65%. Notably, the proportion of individuals with incipient CLAD at the time of a single or repeated ≥20% FEV1 decline was 50% and 71%, respectively. These estimates could inform the development of acute lung allograft dysfunction FEV<sub>1</sub> thresholds as enrollment criteria or surrogate outcome measures.</p>","PeriodicalId":15900,"journal":{"name":"Journal of Heart and Lung Transplantation","volume":" ","pages":""},"PeriodicalIF":6.4000,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Heart and Lung Transplantation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.healun.2024.11.031","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

There is a paucity of data reporting the positive and negative predictive values (PPV, NPV) of acute declines in lung function on chronic lung allograft dysfunction (CLAD). We sought to define the predictive ability of single or repeated forced expiratory volume in the first second (FEV1) declines for at least 3 weeks on the development of CLAD or death by 1-year. We analyzed 340 subjects with at least 3 years of follow-up data from two lung transplant centers. A single ≥10% FEV1 decline had a PPV of 35% and NPV of 63%, and a repeated ≥10% FEV1 decline for at least 3 weeks had a PPV of 44% and NPV of 65%. Notably, the proportion of individuals with incipient CLAD at the time of a single or repeated ≥20% FEV1 decline was 50% and 71%, respectively. These estimates could inform the development of acute lung allograft dysfunction FEV1 thresholds as enrollment criteria or surrogate outcome measures.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性同种异体肺移植功能障碍患者单次和反复FEV1下降≥10%的预后价值
关于肺功能急性下降对慢性同种异体肺移植功能障碍(chronic lung allograft dysfunction, CLAD)的阳性和阴性预测值(PPV, NPV)的报道缺乏数据。我们试图确定单次或反复FEV1下降至少3周或1年内死亡的预测能力。我们对来自两个肺移植中心的340名受试者进行了至少3年的随访。单次FEV1下降≥10%的PPV为35%,NPV为63%,重复≥10%的FEV1下降至少3周的PPV为44%,NPV为65%。值得注意的是,单次或多次FEV1下降≥20%时出现初发性CLAD的个体比例分别为50%和71%。这些估计可以为急性同种异体肺移植功能障碍的发展提供信息,FEV1阈值可以作为入选标准或替代结果测量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
10.10
自引率
6.70%
发文量
1667
审稿时长
69 days
期刊介绍: The Journal of Heart and Lung Transplantation, the official publication of the International Society for Heart and Lung Transplantation, brings readers essential scholarly and timely information in the field of cardio-pulmonary transplantation, mechanical and biological support of the failing heart, advanced lung disease (including pulmonary vascular disease) and cell replacement therapy. Importantly, the journal also serves as a medium of communication of pre-clinical sciences in all these rapidly expanding areas.
期刊最新文献
Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials. Vintage vitality: Embracing older donor lungs for transplants. A perspective on the added value of red blood cells during cardiac hypothermic oxygenated perfusion. Loss of Nr4a1 ameliorates endothelial cell injury and vascular leakage in lung transplantation from circulatory-death donor. Early stroke following durable left ventricular assist device (LVAD) implantation: An analysis of the Society of Thoracic Surgeons Intermacs National Database.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1